GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cassava Sciences Inc (MEX:SAVA) » Definitions » Cyclically Adjusted Price-to-FCF

Cassava Sciences (MEX:SAVA) Cyclically Adjusted Price-to-FCF : (As of Jun. 25, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Cassava Sciences Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cassava Sciences Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Cassava Sciences's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cassava Sciences Cyclically Adjusted Price-to-FCF Chart

Cassava Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cassava Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cassava Sciences's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Cassava Sciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cassava Sciences's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cassava Sciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Cassava Sciences's Cyclically Adjusted Price-to-FCF falls into.



Cassava Sciences Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Cassava Sciences's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Cassava Sciences's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-7.198/131.7762*131.7762
=-7.198

Current CPI (Mar. 2024) = 131.7762.

Cassava Sciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -5.199 100.560 -6.813
201409 -3.466 100.428 -4.548
201412 -5.835 99.070 -7.761
201503 -3.158 99.621 -4.177
201506 -4.718 100.684 -6.175
201509 -6.286 100.392 -8.251
201512 -9.416 99.792 -12.434
201603 -8.348 100.470 -10.949
201606 -9.272 101.688 -12.015
201609 -8.246 101.861 -10.668
201612 -9.562 101.863 -12.370
201703 -4.184 102.862 -5.360
201706 -8.840 103.349 -11.272
201709 -5.971 104.136 -7.556
201712 -4.317 104.011 -5.469
201803 -4.497 105.290 -5.628
201806 -3.236 106.317 -4.011
201809 -2.246 106.507 -2.779
201812 -0.644 105.998 -0.801
201903 -0.703 107.251 -0.864
201906 -0.661 108.070 -0.806
201909 -0.840 108.329 -1.022
201912 -0.612 108.420 -0.744
202003 -1.144 108.902 -1.384
202006 -0.784 108.767 -0.950
202009 -1.921 109.815 -2.305
202012 -0.774 109.897 -0.928
202103 -1.250 111.754 -1.474
202106 -2.560 114.631 -2.943
202109 -7.598 115.734 -8.651
202112 -4.100 117.630 -4.593
202203 -11.936 121.301 -12.967
202206 -6.325 125.017 -6.667
202209 -11.404 125.227 -12.000
202212 -10.032 125.222 -10.557
202303 -5.878 127.348 -6.082
202306 -8.171 128.729 -8.364
202309 -11.012 129.860 -11.175
202312 -8.994 129.419 -9.158
202403 -7.198 131.776 -7.198

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cassava Sciences  (MEX:SAVA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Cassava Sciences Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Cassava Sciences's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cassava Sciences (MEX:SAVA) Business Description

Industry
Traded in Other Exchanges
Address
6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms.